Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin M Posadas

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Nature Communications|April 3, 2020
Loss of testosterone impairs anti-tumor neutrophil functionJanet L Markman, Rebecca A Porritt, Daiko Wakita, et al.
Frontiers in Physiology|March 3, 2022
Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood SamplesRuoxiang Wang, Nicholas N Nissen, Yi Zhang, et al.
The Prostate|October 24, 2015
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium StudyEdwin M Posadas, Rafi S Ahmed, Theodore Karrison, et al.
Cancer|March 26, 2024
A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancerAum J Solanki, Mitchell Kamrava, Edwin M Posadas, et al.
Cancer|October 21, 2015
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital DatabaseBrian T Hanyok, Lauren E Howard, Christopher L Amling, et al.
European Urology Focus|July 30, 2017
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH DatabaseColette A Whitney, Lauren E Howard, Edwin M Posadas, et al.
Urologic Oncology|May 18, 2024
Variation in content discussed by specialty in consultations for clinically localized prostate cancerNadine A Friedrich, Michael Luu, Rebecca Gale, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Journal of Medicinal Chemistry|February 23, 2018
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug ConjugateAhmed F Salem, Si Wang, Sandrine Billet, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Nature Communications|April 3, 2020
Loss of testosterone impairs anti-tumor neutrophil functionJanet L Markman, Rebecca A Porritt, Daiko Wakita, et al.
Frontiers in Physiology|March 3, 2022
Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood SamplesRuoxiang Wang, Nicholas N Nissen, Yi Zhang, et al.
The Prostate|October 24, 2015
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium StudyEdwin M Posadas, Rafi S Ahmed, Theodore Karrison, et al.
Cancer|March 26, 2024
A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancerAum J Solanki, Mitchell Kamrava, Edwin M Posadas, et al.
Cancer|October 21, 2015
Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital DatabaseBrian T Hanyok, Lauren E Howard, Christopher L Amling, et al.
European Urology Focus|July 30, 2017
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH DatabaseColette A Whitney, Lauren E Howard, Edwin M Posadas, et al.
Urologic Oncology|May 18, 2024
Variation in content discussed by specialty in consultations for clinically localized prostate cancerNadine A Friedrich, Michael Luu, Rebecca Gale, et al.
Cancer|June 15, 2007
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingEdwin M Posadas, Virginia Kwitkowski, Herbert L Kotz, et al.
Journal of Medicinal Chemistry|February 23, 2018
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug ConjugateAhmed F Salem, Si Wang, Sandrine Billet, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Pageof 12